A Phase II Study of Temsirolimus (CCI-779) in Combination with Rituximab in Patients with Relapsed or Refractory Mantle Cell Lymphoma.

被引：4

作者：

Ansell, Stephen M. ^{[1
]}

Tang, Hui

Kurtin, Paul

Koenig, Patricia

Inwards, David J. ^{[1
]}

Shah, Keith ^{[2
]}

Witzig, Thomas E. ^{[1
]}

机构：

[1] Mayo Clin, Coll Med, Rochester, MN USA

[2] Dayton Oncol Hematol Consultants, Dayton, OH USA

来源：

BLOOD | 2009年 / 114卷 / 22期

关键词：

D O I：

10.1182/blood.V114.22.1665.1665

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：664 / 665

页数：2

共 50 条

[1] Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma
Witzig, TE
Geyer, SM
Ghobrial, I
Inwards, DJ
Fonseca, R
Kurtin, P
Ansell, SM
Luyun, R
Flynn, PJ
Morton, RF
Dakhil, SR
Gross, H
Kaufmann, SH
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (23) : 5347 - 5356
[2] Final results of a phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma
Witzig, T
Geyer, S
Ghobrial, I
Inwards, D
Fonseca, R
Kurtin, P
Ansell, S
Kaufmann, S
ANNALS OF ONCOLOGY, 2005, 16 : 65 - 65
[3] Phase II Trial of Weekly Bortezomib in Combination with CCI-779 (temsirolimus) in Relapsed or Relapsed/Refractory Multiple Myeloma
Ghobrial, Irene M.
Vij, Ravi
Munshi, Nikhil C.
Schlossman, Robert L.
Laubach, Jacob
Campagnaro, Erica L.
Leduc, Renee
Rourke, Meghan
Chuma, Stacey
Kunsman, Janet
Dollard, Akari M.
Warren, Diane
Harris, Brianna
Sam, Amy
Anderson, Kenneth C.
Richardson, Paul
BLOOD, 2009, 114 (22) : 311 - 312
[4] Activity of the mammalian target of rapamycin inhibitor temsirolimus (CCI-779) in relapsed mantle cell lymphoma
不详
CLINICAL LYMPHOMA, 2004, 5 (03): : 144 - 145
[5] Temsirolimus and rituximab in patients with relapsed or refractory mantle cell lymphoma: a phase 2 study
Ansell, Stephen M.
Tang, Hui
Kurtin, Paul J.
Koenig, Patricia A.
Inwards, David J.
Shah, Keith
Ziesmer, Steven C.
Feldman, Andrew L.
Rao, Radha
Gupta, Mamta
Erlichman, Charles
Witzig, Thomas E.
LANCET ONCOLOGY, 2011, 12 (04): : 361 - 368
[6] A phase II study of temsirolimus (CCI-779) in patients with advanced leukemias.
Yee, KWL
Garcia-Manero, G
Thomas, D
Ani, FRK
Verstovsek, S
Andreeff, M
Dancey, JE
Giles, FJ
BLOOD, 2004, 104 (11) : 214B - 214B
[7] Final Results of the Phase I/II Trial of Weekly Bortezomib In Combination with Temsirolimus (CCI-779) In Relapsed or Relapsed/Refractory Multiple Myeloma Specifically In Patients Refractory to Bortezomib
Ghobrial, Irene M.
Weller, Edie
Vij, Ravi
Munshi, Nikhil C.
Banwait, Ranjit
Rourke, Meghan
Schlossman, Robert L.
Laubach, Jacob P.
Jakubowiak, Andrzej J.
Leduc, Renee
Chuma, Stacey
Kunsman, Janet
Dollard, Akari M.
Warren, Diane
Harris, Brianna
Poon, Tiffany
Sam, Amy
Rodig, Scott J.
Anderson, Kenneth C.
Richardson, Paul G.
BLOOD, 2010, 116 (21) : 435 - 436
[8] Phase II trial of temsirolimus (CCI-779) in patients with relapsed or refractory multiple myeloma (MM): Preliminary results.
Farag, S. S.
Zhang, S.
Miller, M.
Buckner, M.
Kraut, E.
Chan, K.
Eng, C.
Byrd, J. C.
Dancey, J. E.
Grever, M. R.
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 450S - 450S
[9] Phase I Trial of CCI-779 (Temsirolimus) and Weekly Bortezomib in Relapsed and/or Refractory Multiple Myeloma.
Ghobrial, Irene M.
Munshi, Nikhil
Schlossman, Robert
Chuma, Stacey
Leduc, Renee
Nelson, Marybeth
Sam, Amy
O'Connor, Kelly
Harris, Brianna
Warren, Diane
Dollard, Akari M.
Laubach, Jacob
Vij, Ravi
Campagnaro, Erica
Birner, Ann
Dixon-Lipscomb, Virginia
Anderson, Kenneth C.
Richardson, Paul G.
BLOOD, 2008, 112 (11) : 1266 - 1266
[10] A Phase I/II Study of Lenalidomide in Combination with Rituximab in Relapsed/Refractory Mantle Cell Lymphoma
Wang, Luhua
Fayad, Luis
Hagemeister, Fredrick B.
Neelapu, Sattva
Samaniego, Felipe
McLaughlin, Peter
Samuels, Barry
Yi, Qing
Pro, Barbara
Fanale, Michelle
Shah, Jatin
Younes, Anas
Bell, Neda
Knight, Robert
Zeldis, Jerome B.
Cabanillas, Fernando
Kwak, Larry
Romaguera, Jorge
BLOOD, 2009, 114 (22) : 1064 - 1065

← 1 2 3 4 5 →